Estimated reduction in revenue for the US older adult market, based on updated ACIP recommendations in 2024 The US market for RSV vaccines for the elderly could have generated sales of $3.7bn in 2024 ...
London, England, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Today, Airfinity is launching the world’s first data and analytics platform dedicated to the breakthrough obesity treatments market. The platform ...
New analysis by Airfinity and Bloomberg News reveals outbreaks of diseases such as measles, whooping cough, tuberculosis and polio, as well as dengue and cholera are surging worldwide. London, England ...
Dwindling demand for Covid antivirals is poised to offset strong sales from the first half of 2022, according to health analytics firm Airfinity, as officials in the U.S. and around the world urge ...
BERLIN (Reuters) -The suspension of Johnson & Johnson's coronavirus vaccine could delay efforts to inoculate most people in the European Union by over two months, scientific information and analytics ...
London, England, July 24, 2024 (GLOBE NEWSWIRE) -- Airfinity has reduced its sales projections for vaccines against Respiratory Syncytial Virus (RSV) for older adults in the US from $4.7bn per year to ...
US revenue for RSV vaccines to be stunted as booster shots are not recommended due to concerns about the risk versus benefit of additional doses. London, England, July 24, 2024 (GLOBE NEWSWIRE) -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results